Innovation Pharmaceuticals Inc (IPIX)

[Lemoncat]

I was hoping for something to come out of it that would apply to the real world and move the share price.

That's why the upcoming trial results are so important. We saw with Remdesivir that robust antiviral activity alone did not translate into great clinical results.

1. Is the dosage we're able to give, enough to elicit a good clinical response? This is why I have said Selectivity Index, which thankfully isn't mentioned here much anymore, is completely useless when you have a systemic dosage ceiling.

2. Does the anti-inflammatory properties of Brilacidin significantly boost clinical performance beyond what we would expect of an antiviral alone? Remdesivir being the anti-viral available for comparison.

Go IPIX!